Trabectedin  	Trabectedin  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
relapsed  	relapsed  	 JJ	O
ovarian  	ovarian  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
The  	The  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
trabectedin  	trabectedin  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
relapsed  	relapsed  	 JJ	O
platinum-sensitive  	platinum-sensitive  	 JJ	B-NP
ovarian  	ovarian  	 JJ	I-NP
cancer 	cancer 	 NN	I-NP
,  	,  	 ,	O
based  	based  	 VBN	O
upon  	upon  	 IN	O
a  	a  	 DT	O
review  	review  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
National  	National  	 NNP	O
Institute  	Institute  	 NNP	O
for  	for  	 IN	O
Health  	Health  	 NNP	O
and  	and  	 CC	O
Clinical  	Clinical  	 NNP	B-NP
Excellence  	Excellence  	 NNP	I-NP
( 	( 	 -LRB-	O
NICE 	NICE 	 NNP	O
)  	)  	 -RRB-	O
as  	as  	 IN	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
single  	single  	 JJ	O
technology  	technology  	 NN	B-NP
appraisal  	appraisal  	 NN	I-NP
process 	process 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
submission  	submission  	 NN	O
addressed  	addressed  	 VBD	O
only  	only  	 JJ	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
decision  	decision  	 NN	B-NP
problem  	problem  	 NN	I-NP
and  	and  	 CC	O
did  	did  	 VBD	O
not  	not  	 RB	O
provide  	provide  	 VB	O
evidence  	evidence  	 NN	O
to  	to  	 TO	O
compare  	compare  	 VB	O
trabectedin  	trabectedin  	 NNS	B-NP
( 	( 	 -LRB-	O
Yondelis® 	Yondelis® 	 NNP	B-NP
,  	,  	 ,	O
PharmaMar 	PharmaMar 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
pegylated  	pegylated  	 FW	B-NP
liposomal  	liposomal  	 FW	I-NP
doxorubicin  	doxorubicin  	 FW	I-NP
hydrochloride  	hydrochloride  	 FW	I-NP
( 	( 	 -LRB-	O
PLDH 	PLDH 	 NNP	B-NP
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
Caelyx® 	Caelyx® 	 NNP	B-NP
,  	,  	 ,	O
Schering-Plough 	Schering-Plough 	 NNP	B-NP
)  	)  	 -RRB-	O
with  	with  	 IN	O
key  	key  	 JJ	B-NP
comparators 	comparators 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
submission 	submission 	 NN	O
's  	's  	 POS	O
direct  	direct  	 JJ	O
comparison  	comparison  	 NN	B-NP
evidence  	evidence  	 NN	I-NP
came  	came  	 VBD	O
from  	from  	 IN	O
one  	one  	 CD	O
reasonable-quality  	reasonable-quality  	 JJ	B-NP
randomised  	randomised  	 NNS	O
controlled  	controlled  	 VBN	B-NP
trial  	trial  	 NN	I-NP
( 	( 	 -LRB-	O
RCT 	RCT 	 NNP	B-NP
)  	)  	 -RRB-	O
of  	of  	 IN	O
trabectedin  	trabectedin  	 NN	B-NP
and  	and  	 CC	O
PLDH  	PLDH  	 NNP	B-NP
versus  	versus  	 FW	O
PLDH  	PLDH  	 FW	B-NP
alone  	alone  	 FW	O
( 	( 	 -LRB-	O
ET743-OVA-301 	ET743-OVA-301 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
results  	results  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
RCT  	RCT  	 NNP	B-NP
were  	were  	 VBD	O
subdivided  	subdivided  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
entire  	entire  	 JJ	O
platinum-sensitive  	platinum-sensitive  	 JJ	B-NP
population  	population  	 NN	I-NP
( 	( 	 -LRB-	O
>  	>  	 CD	O
6-month  	6-month  	 CD	O
relapse  	relapse  	 NN	O
after  	after  	 IN	O
initial  	initial  	 JJ	O
platinum-based  	platinum-based  	 JJ	O
chemotherapy 	chemotherapy 	 NN	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
partially  	partially  	 RB	O
platinum-sensitive  	platinum-sensitive  	 JJ	O
( 	( 	 -LRB-	O
≥  	≥  	 CD	O
6-  	6-  	 CD	O
to  	to  	 TO	O
12-month  	12-month  	 JJ	O
relapse 	relapse 	 NN	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
fully  	fully  	 RB	O
platinum-sensitive  	platinum-sensitive  	 JJ	O
( 	( 	 -LRB-	O
>  	>  	 CD	O
12-month  	12-month  	 JJ	O
relapse 	relapse 	 NN	O
)  	)  	 -RRB-	O
populations 	populations 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
outcomes  	outcomes  	 NN	O
included  	included  	 VBD	O
were  	were  	 VBD	O
overall  	overall  	 JJ	O
survival 	survival 	 NN	O
,  	,  	 ,	O
progression-free  	progression-free  	 JJ	B-NP
survival  	survival  	 NN	I-NP
measured  	measured  	 VBN	O
by  	by  	 IN	O
three  	three  	 CD	O
types  	types  	 NNS	O
of  	of  	 IN	O
assessor 	assessor 	 NN	O
,  	,  	 ,	O
response  	response  	 NN	B-NP
rates 	rates 	 NNS	I-NP
,  	,  	 ,	O
adverse  	adverse  	 JJ	O
effects  	effects  	 NNS	O
of  	of  	 IN	O
treatment 	treatment 	 NN	O
,  	,  	 ,	O
health-related  	health-related  	 JJ	O
quality  	quality  	 NN	O
of  	of  	 IN	O
life  	life  	 NN	O
and  	and  	 CC	O
cost  	cost  	 NN	O
per  	per  	 IN	O
quality-adjusted-life-year  	quality-adjusted-life-year  	 NNP	B-NP
( 	( 	 -LRB-	O
QALY 	QALY 	 NNP	B-NP
)  	)  	 -RRB-	O
gained 	gained 	 VBD	O
.  	.  	 .	O
A  	A  	 DT	O
mixed  	mixed  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
comparison  	comparison  	 NN	I-NP
( 	( 	 -LRB-	O
MTC 	MTC 	 NNP	B-NP
)  	)  	 -RRB-	O
meta-analysis  	meta-analysis  	 JJ	B-NP
comparing  	comparing  	 JJ	O
trabectedin  	trabectedin  	 NN	B-NP
and  	and  	 CC	O
PLDH  	PLDH  	 NNP	B-NP
with  	with  	 IN	O
single-agent  	single-agent  	 JJ	B-NP
PLDH  	PLDH  	 NN	I-NP
within  	within  	 IN	O
the  	the  	 DT	O
entire  	entire  	 JJ	O
platinum-sensitive  	platinum-sensitive  	 JJ	B-NP
population 	population 	 NN	I-NP
,  	,  	 ,	O
with  	with  	 IN	O
paclitaxel  	paclitaxel  	 NN	B-NP
or  	or  	 CC	O
with  	with  	 IN	O
topotecan  	topotecan  	 VBG	O
also  	also  	 RB	O
formed  	formed  	 VBN	B-NP
part  	part  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
submission 	submission 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
RCT  	RCT  	 NNP	B-NP
data  	data  	 NNS	I-NP
showed  	showed  	 VBD	O
that  	that  	 DT	O
trabectedin  	trabectedin  	 NN	B-NP
plus  	plus  	 CC	O
PLDH  	PLDH  	 NNP	B-NP
compared  	compared  	 VBN	O
with  	with  	 IN	O
PLDH  	PLDH  	 NNP	B-NP
monotherapy  	monotherapy  	 NN	I-NP
had  	had  	 VBD	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
effect  	effect  	 NN	O
on  	on  	 IN	O
overall  	overall  	 JJ	O
survival  	survival  	 NN	O
only  	only  	 RB	O
within  	within  	 IN	O
the  	the  	 DT	O
partially  	partially  	 RB	O
platinum-sensitive  	platinum-sensitive  	 JJ	B-NP
subgroup 	subgroup 	 NN	I-NP
.  	.  	 .	O
PFS  	PFS  	 NNP	B-NP
results  	results  	 NNS	I-NP
reported  	reported  	 VBD	O
by  	by  	 IN	O
the  	the  	 DT	O
independent  	independent  	 JJ	O
radiologists  	radiologists  	 NN	O
showed  	showed  	 VBD	O
significant  	significant  	 JJ	O
effects  	effects  	 NNS	O
in  	in  	 IN	O
favour  	favour  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
trabectedin  	trabectedin  	 NN	B-NP
and  	and  	 CC	O
PLDH  	PLDH  	 NNP	B-NP
arm  	arm  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
entire  	entire  	 JJ	O
and  	and  	 CC	O
partially  	partially  	 RB	O
platinum-sensitive  	platinum-sensitive  	 JJ	B-NP
populations  	populations  	 NNS	I-NP
only 	only 	 RB	O
.  	.  	 .	O
Rates  	Rates  	 NNS	O
of  	of  	 IN	O
grade  	grade  	 CD	O
3  	3  	 CD	O
and  	and  	 CC	O
4  	4  	 CD	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
were  	were  	 VBD	O
mostly  	mostly  	 RB	O
higher  	higher  	 JJR	O
in  	in  	 IN	O
the  	the  	 DT	O
trabectedin  	trabectedin  	 NN	B-NP
and  	and  	 CC	O
PLDH  	PLDH  	 NNP	B-NP
arm  	arm  	 NN	I-NP
than  	than  	 IN	O
in  	in  	 IN	O
the  	the  	 DT	O
PLDH  	PLDH  	 NNP	B-NP
alone  	alone  	 JJ	O
arm 	arm 	 NN	O
.  	.  	 .	O
There  	There  	 EX	O
were  	were  	 VBD	O
several  	several  	 JJ	O
issues  	issues  	 NNS	O
regarding  	regarding  	 VBG	O
the  	the  	 DT	O
undertaking  	undertaking  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
MTC 	MTC 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
thus  	thus  	 RB	O
the  	the  	 DT	O
data  	data  	 NNS	O
were  	were  	 VBD	O
not  	not  	 RB	O
considered  	considered  	 VBN	O
robust 	robust 	 JJ	O
.  	.  	 .	O
Furthermore 	Furthermore 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
ERG  	ERG  	 NNP	O
did  	did  	 VBD	O
not  	not  	 RB	O
believe  	believe  	 VB	O
the  	the  	 DT	O
MTC  	MTC  	 NNP	B-NP
to  	to  	 TO	O
be  	be  	 VB	O
necessary  	necessary  	 JJ	O
to  	to  	 TO	O
answer  	answer  	 VB	O
the  	the  	 DT	O
decision  	decision  	 NN	B-NP
problem 	problem 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
submitted  	submitted  	 VBD	O
a  	a  	 DT	O
de  	de  	 FW	B-NP
novo  	novo  	 FW	I-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
model 	model 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
main  	main  	 JJ	O
analysis  	analysis  	 NN	O
compared  	compared  	 VBN	O
trabectedin  	trabectedin  	 VBN	O
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
PLDH  	PLDH  	 NNP	B-NP
versus  	versus  	 FW	O
paclitaxel 	paclitaxel 	 FW	B-NP
,  	,  	 ,	O
topotecan  	topotecan  	 NN	B-NP
and  	and  	 CC	O
PLDH  	PLDH  	 NNP	B-NP
( 	( 	 -LRB-	O
each  	each  	 DT	O
as  	as  	 IN	O
monotherapy 	monotherapy 	 CD	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
the  	the  	 DT	O
entire  	entire  	 JJ	O
platinum-sensitive  	platinum-sensitive  	 JJ	B-NP
population 	population 	 NN	I-NP
,  	,  	 ,	O
using  	using  	 VBG	O
results  	results  	 NNS	O
estimated  	estimated  	 VBN	O
from  	from  	 IN	O
the  	the  	 DT	O
MTC 	MTC 	 NNP	B-NP
.  	.  	 .	O
Additional  	Additional  	 JJ	B-NP
analyses  	analyses  	 NNS	I-NP
were  	were  	 VBD	O
presented  	presented  	 VBN	O
comparing  	comparing  	 VBG	B-NP
trabectedin  	trabectedin  	 NN	I-NP
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
PLDH  	PLDH  	 NNP	B-NP
versus  	versus  	 CC	O
PLDH  	PLDH  	 NNP	B-NP
monotherapy  	monotherapy  	 VBZ	O
using  	using  	 VBG	O
direct  	direct  	 JJ	O
evidence  	evidence  	 NN	O
from  	from  	 IN	O
the  	the  	 DT	O
OVA-301  	OVA-301  	 JJ	B-NP
trial  	trial  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
fully 	fully 	 RB	O
,  	,  	 ,	O
partially  	partially  	 RB	O
and  	and  	 CC	O
entire  	entire  	 JJ	O
platinum-sensitive  	platinum-sensitive  	 JJ	B-NP
populations 	populations 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
cost  	cost  	 NN	O
per  	per  	 IN	O
QALY  	QALY  	 NNP	B-NP
gained  	gained  	 VBD	O
for  	for  	 IN	O
trabectedin  	trabectedin  	 NN	B-NP
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
PLDH  	PLDH  	 NNP	B-NP
versus  	versus  	 CC	O
PLDH  	PLDH  	 NNP	B-NP
monotherapy  	monotherapy  	 NN	I-NP
was  	was  	 VBD	O
estimated  	estimated  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
£  	£  	 CD	O
70,076  	70,076  	 CD	O
in  	in  	 IN	O
the  	the  	 DT	O
main  	main  	 JJ	O
analysis 	analysis 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
additional  	additional  	 JJ	O
analyses 	analyses 	 NNS	O
,  	,  	 ,	O
the  	the  	 DT	O
cost  	cost  	 NN	O
per  	per  	 IN	O
QALY  	QALY  	 NNP	B-NP
gained  	gained  	 VBD	O
for  	for  	 IN	O
trabectedin  	trabectedin  	 NN	B-NP
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
PLDH  	PLDH  	 NNP	B-NP
versus  	versus  	 CC	O
PLDH  	PLDH  	 NNP	B-NP
monotherapy  	monotherapy  	 NN	I-NP
was  	was  	 VBD	O
£  	£  	 CD	O
94,832 	94,832 	 CD	O
,  	,  	 ,	O
£  	£  	 NNP	O
43,996  	43,996  	 NNP	O
and  	and  	 CC	O
£  	£  	 CD	O
31,092  	31,092  	 CD	O
for  	for  	 IN	O
the  	the  	 DT	O
entire 	entire 	 JJ	O
,  	,  	 ,	O
partially  	partially  	 RB	O
and  	and  	 CC	O
fully  	fully  	 RB	O
platinum-sensitive  	platinum-sensitive  	 JJ	B-NP
populations 	populations 	 NNS	I-NP
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
Additional  	Additional  	 JJ	B-NP
work  	work  	 NN	I-NP
was  	was  	 VBD	O
undertaken  	undertaken  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
ERG  	ERG  	 NNP	O
using  	using  	 VBG	O
patient-level  	patient-level  	 JJ	B-NP
data  	data  	 NNS	I-NP
and  	and  	 CC	O
amending  	amending  	 VBG	O
some  	some  	 DT	O
assumptions  	assumptions  	 NNS	O
to  	to  	 TO	O
provide  	provide  	 VB	O
a  	a  	 DT	O
better  	better  	 RBR	O
statistical  	statistical  	 JJ	B-NP
fit  	fit  	 NN	I-NP
to  	to  	 TO	O
the  	the  	 DT	O
Kaplan-Meier  	Kaplan-Meier  	 JJ	B-NP
data  	data  	 NNS	I-NP
than  	than  	 IN	O
the  	the  	 DT	O
exponential  	exponential  	 JJ	B-NP
distribution  	distribution  	 NN	I-NP
assumed  	assumed  	 VBD	O
by  	by  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
ERG  	ERG  	 NNP	B-NP
base-case  	base-case  	 JJ	I-NP
estimate  	estimate  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
cost  	cost  	 NN	O
per  	per  	 IN	O
QALY  	QALY  	 NNP	B-NP
of  	of  	 IN	I-NP
trabectedin  	trabectedin  	 NN	I-NP
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
PLDH  	PLDH  	 NNP	B-NP
ranged  	ranged  	 VBD	O
from  	from  	 IN	O
£46,503  	£46,503  	 CD	O
to  	to  	 TO	O
£54,607  	£54,607  	 CD	O
in  	in  	 IN	O
the  	the  	 DT	O
partially  	partially  	 RB	O
platinum-sensitive  	platinum-sensitive  	 JJ	B-NP
population 	population 	 NN	I-NP
.  	.  	 .	O
At  	At  	 IN	O
the  	the  	 DT	O
time  	time  	 NN	O
of  	of  	 IN	O
writing 	writing 	 NN	O
,  	,  	 ,	O
trabectedin  	trabectedin  	 VBG	O
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
PLDH  	PLDH  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
women  	women  	 NNS	O
with  	with  	 IN	O
relapsed  	relapsed  	 JJ	O
platinum-sensitive  	platinum-sensitive  	 JJ	B-NP
ovarian  	ovarian  	 JJ	I-NP
cancer  	cancer  	 NN	I-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
recommended  	recommended  	 VBN	O
by  	by  	 IN	O
NICE  	NICE  	 NNP	O
in  	in  	 IN	O
the  	the  	 DT	O
final  	final  	 JJ	B-NP
appraisal  	appraisal  	 NN	I-NP
determination 	determination 	 NN	I-NP
.  	.  	 .	O
